Abbott Laboratories is projected to report Q3 2026 revenue of $11.21 billion and adjusted EPS of $1.42, with shares currently trading at $128.45 against an average analyst price target of $145.20.
Investors are specifically monitoring organic sales growth within the Medical Devices segment, particularly the FreeStyle Libre continuous glucose monitoring system's performance for the quarter.
Market focus remains on the adoption of new biowearable lines and any updates regarding ongoing NEC litigation developments that have recently impacted investor sentiment. Analysts expect strong contributions from the structural heart and electrophysiology divisions to drive margin expansion and offset moderate growth in the nutrition segment.